BACKGROUND: Endothelial dysfunction is a critical intermediate phenotype in the pathogenesis of cardiovascular disease. We evaluated the relative contributions of distinct biological pathways to interindividual variation in endothelial function by relating prototype biomarkers (representing these pathways) to brachial artery vasodilator function. METHODS AND RESULTS: We investigated the cross-sectional relations of a panel of 7 biomarkers measured at a routine examination to brachial artery vasodilator function (flow-mediated dilation [FMD] and reactive hyperemia) assessed at a subsequent examination (mean interval, 2.9 years) in 2113 Framingham Heart Study participants (mean age, 61 years; 54% women). We selected biomarkers from 4 biological domains: neurohormonal (N-terminal pro-atrial natriuretic peptide [N-ANP], B-type natriuretic peptide [BNP], renin, aldosterone), hemostatic factors (plasminogen activator inhibitor-1 [PAI-1]), inflammation (C-reactive protein [CRP]), and target organ damage (urine albumin-creatinine ratio). In age- and sex-adjusted models, several biomarkers were related to baseline brachial artery diameter (PAI-1, CRP, urine albumin-creatinine ratio), baseline mean flow (N-ANP, BNP, PAI-1, CRP, aldosterone), FMD (N-ANP, PAI-1, CRP, renin), and reactive hyperemia (BNP, PAI-1, CRP, renin, urine albumin-creatinine ratio). In multivariable analyses relating the 7 biomarkers conjointly to each vascular function measure (adjusting for known risk factors), N-ANP and renin were positively related to FMD (P=0.001 and P=0.04, respectively), and N-ANP was inversely related to baseline mean flow velocity (P=0.01). None of the other biomarkers was significantly related to the vascular function measures studied. CONCLUSIONS: In our large community-based sample, a conservative strategy relating several biomarkers to vascular endothelial function identified plasma N-ANP as a key correlate of mean flow under basal conditions and of FMD in response to forearm cuff occlusion.
BACKGROUND: Endothelial dysfunction is a critical intermediate phenotype in the pathogenesis of cardiovascular disease. We evaluated the relative contributions of distinct biological pathways to interindividual variation in endothelial function by relating prototype biomarkers (representing these pathways) to brachial artery vasodilator function. METHODS AND RESULTS: We investigated the cross-sectional relations of a panel of 7 biomarkers measured at a routine examination to brachial artery vasodilator function (flow-mediated dilation [FMD] and reactive hyperemia) assessed at a subsequent examination (mean interval, 2.9 years) in 2113 Framingham Heart Study participants (mean age, 61 years; 54% women). We selected biomarkers from 4 biological domains: neurohormonal (N-terminal pro-atrial natriuretic peptide [N-ANP], B-type natriuretic peptide [BNP], renin, aldosterone), hemostatic factors (plasminogen activator inhibitor-1 [PAI-1]), inflammation (C-reactive protein [CRP]), and target organ damage (urine albumin-creatinine ratio). In age- and sex-adjusted models, several biomarkers were related to baseline brachial artery diameter (PAI-1, CRP, urine albumin-creatinine ratio), baseline mean flow (N-ANP, BNP, PAI-1, CRP, aldosterone), FMD (N-ANP, PAI-1, CRP, renin), and reactive hyperemia (BNP, PAI-1, CRP, renin, urine albumin-creatinine ratio). In multivariable analyses relating the 7 biomarkers conjointly to each vascular function measure (adjusting for known risk factors), N-ANP and renin were positively related to FMD (P=0.001 and P=0.04, respectively), and N-ANP was inversely related to baseline mean flow velocity (P=0.01). None of the other biomarkers was significantly related to the vascular function measures studied. CONCLUSIONS: In our large community-based sample, a conservative strategy relating several biomarkers to vascular endothelial function identified plasma N-ANP as a key correlate of mean flow under basal conditions and of FMD in response to forearm cuff occlusion.
Authors: Karin F Hoth; David F Tate; Athena Poppas; Daniel E Forman; John Gunstad; David J Moser; Robert H Paul; Angela L Jefferson; Andreana P Haley; Ronald A Cohen Journal: Stroke Date: 2007-01-04 Impact factor: 7.914
Authors: Ronald A Cohen; Athena Poppas; Daniel E Forman; Karin F Hoth; Andreana P Haley; John Gunstad; Angela L Jefferson; David F Tate; Robert H Paul; Lawrence H Sweet; Mokato Ono; Beth A Jerskey; Marie Gerhard-Herman Journal: J Clin Exp Neuropsychol Date: 2008-06-16 Impact factor: 2.475
Authors: Sushan Yang; Shi Huang; Lori B Daniels; Joseph Yeboah; Joao A C Lima; Valentina Cannone; John C Burnett; Joshua A Beckman; J Jeffrey Carr; Thomas J Wang; Deepak K Gupta Journal: Heart Date: 2019-05-31 Impact factor: 5.994
Authors: Justin P Zachariah; Vanessa Xanthakis; Martin G Larson; Joseph A Vita; Lisa M Sullivan; Holly M Smith; Radwan Safa; Xuyang Peng; Naomi Hamburg; Daniel Levy; Douglas B Sawyer; Gary F Mitchell; Ramachandran S Vasan Journal: Hypertension Date: 2012-02-27 Impact factor: 10.190
Authors: Merry L Lindsey; Yonggang Ma; Elizabeth R Flynn; Michael D Winniford; Michael E Hall; Kristine Y DeLeon-Pennell Journal: Biochim Biophys Acta Mol Basis Dis Date: 2018-09-20 Impact factor: 5.187
Authors: Nisha I Parikh; Michelle J Keyes; Martin G Larson; Karla M Pou; Naomi M Hamburg; Joseph A Vita; Christopher J O'Donnell; Ramachandran S Vasan; Gary F Mitchell; Udo Hoffmann; Caroline S Fox; Emelia J Benjamin Journal: Obesity (Silver Spring) Date: 2009-03-12 Impact factor: 5.002
Authors: Charlotte Andersson; Danielle Enserro; Lisa Sullivan; Thomas J Wang; James L Januzzi; Emelia J Benjamin; Joseph A Vita; Naomi M Hamburg; Martin G Larson; Gary F Mitchell; Ramachandran S Vasan Journal: Atherosclerosis Date: 2016-02-18 Impact factor: 5.162
Authors: Jacob Joseph; Michael J Pencina; Thomas J Wang; Laura Hayes; Geoffrey H Tofler; Paul Jacques; Jacob Selhub; Daniel Levy; Ralph B D'Agostino; Emelia J Benjamin; Ramachandran S Vasan Journal: J Hypertens Date: 2009-06 Impact factor: 4.844